TSLP inhibitor Tezspire clinically has validated Thymic Stromal LymphoPoietin (TSLP) as a valid target for treatment of inflammatory diseases by its approval in late 2021 in the US and in 2022 in ...

A study published in July 2025 issue of Journal of Allergy and Clinical Immunology Global highlighted persistent challenges and fragmented care in managing individuals with severe asthma with an ...

Primary care physicians play a vital role in identifying red flags for rare eosinophilic diseases like HES and EGPA, enabling ...

The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the ...

Conclusions: Non-eosinophilic asthma represents a pathologically distinct disease phenotype which is characterised by the absence of airway eosinophilia, normal subepithelial layer thickness and a ...

Background Two distinct, stable inflammatory phenotypes have been described in adults with asthma: eosinophilic and non-eosinophilic. Treatment strategies based on these phenotypes have been ...

Current prescribing recommendations of serum IgE and blood eosinophils will not influence eligibility or enrolment. The primary outcome is the 52-week asthma attack rate. Bayesian analysis using ...

Canonical pathway analysis revealed upregulation of type 2 immune response and asthma-related pathways in eosinophilic patients. After 12 weeks of inhaled corticosteroid treatment, the eosinophilic ...

To assess the prognostic value of measuring pretreatment baseline blood eosinophil levels in adults receiving systemic treatment for any stage of non-small cell lung cancer.

Eosinophilic patients and non-eosinophilic patients showed no significant difference in in-hospital mortality rates (11% vs 11.8%).

With the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis. The FDA on Wednesday ...